Skip to main content

Leadiant Biosciences to Collaborate with National Institutes of Health on Therapy in Late-Stage Development for GNE Myopathy

By Uncategorized

Leadiant Biosciences, Inc. today announced it has entered into a license agreement and cooperative research and development agreement (CRADA) with the National Institutes of Health (NIH) to develop oral N-acetyl-D-mannosamine (ManNAc) for the potential treatment of individuals with GNE myopathy. GNE myopathy is a rare genetic disorder that causes progressive skeletal muscle atrophy, with an onset in young adulthood, leading to severe disability.

Read More

: URGENT Abelcet® Recall Notification for Healthcare Professional Providers – Read More Here
URGENT Abelcet® Recall Notification for Pharmacy Providers – Read More Here